newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development